JE Cleantech (JCSE) Announces Strong Growth in Q3 2022 ACN Newswire

JE Cleantech (JCSE) Announces Strong Growth in Q3 2022

SINGAPORE, Nov 30, 2022 - (ACN Newswire via SEAPRWire.com) - JE Cleantech Holdings Limited (Nasdaq: JCSE), ("the Company") a Singapore-based cleantech company, today announced encouraging Q3 financial results, for the three months period ended 30 September 2022 (the "reporting period"). During the reporting period, the Company has maintained strong growth in its overall business performance with revenue that more than doubled and a strong turnaround in net income.For the three months period ended September 30, 2022, the Company's total revenue increased by approximately S$3.5 million or 141.8% to approximately S$5.9 million from approximately S$2.4 million in the quarter ended September 30, 2021. The increase was mainly derived from the increase in revenue generated from the Company's sale of cleaning systems and other equipment business of approximately S$3.2 million and the provision of centralized dishwashing and ancillary services business of approximately S$0.3 million, attributable to the post COVID-19 recovery of business.Net income of the Company for the reporting period amounted to approximately S$0.6 million, compared to a net loss of approximately S$0.2 million in the same period last year, indicating a significant turnaround for its business performance.During the reporting period, the Company recorded a gross profit margin of approximately 26.0%, an increase of 63.5% year-over-year. Diluted Earnings Per Share was approximately S$0.05, compared to the basic losses per share of approximately S$0.01 during the same period in 2021. Ms. Bee Yin Hong, CEO and Founder, JE Cleantech said, "We are excited to announce that JE Cleantech has performed well during Q3 2022. Our Q3 results reflect our strong focus on exploiting the rapid recovery of the electronic manufacturing and F&B sectors. As a leading manufacturer of precision cleaning systems and provider of centralized dishwashing and ancillary services in Singapore, we will continue to drive our long-term expansion plans".JE Cleantech has been providing centralized dishwashing services in Singapore since 2013, for customers in various industries, including HDD manufacturing, semiconductor manufacturing, food and beverage, and public transportation. The Company's revenue contributes approximately 15 per cent market share in 2020 in terms of revenue (source: Euromonitor estimates from desk research and trade interviews with leading centralized dishwashing services providers and the relevant trade associations in Singapore). Moving forward, the Company will persistently spare no efforts in further expanding its business, widening its product offerings to more industries, growing its market share, and generating long-term and sustainable returns for its shareholders and investors.About JE Cleantech Holdings LimitedJE Cleantech Holdings Limited is based in Singapore and is principally engaged in (i) the sale of cleaning systems and other equipment; and (ii) the provision of centralized dishwashing and ancillary services. Through its subsidiary, JCS-Echigo Pte Ltd, the company designs, develops, manufactures, and sells cleaning systems for various industrial end-use applications primarily to customers in Singapore and Malaysia. Its cleaning systems are mainly designed for precision cleaning, with features such as particle filtration, ultrasonic or megasonic rinses with a wide range of frequencies, high pressure drying technology, high flow rate spray, and deionized water rinses, which are designed for effective removal of contaminants and to minimize particle generation and entrapment. The Company also has provided centralized dishwashing services, through its subsidiary, Hygieia Warewashing Pte Ltd, since 2013 and general cleaning services since 2015, both mainly for food and beverage establishments in Singapore. http://www.jecleantech.sg/[1] These financial and other data for the three months and nine months periods ended September 30, 2021 and 2022 have not been audited or reviewed by the Auditors.Disclaimer: Forward looking statementsThis news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements may be identified by such words or phrases as "should," "intends," "is subject to," "expects," "will," "continue," "anticipate," "estimated," "projected," "may," "I or we believe," "future prospects," "our strategy," or similar expressions. Forward-looking statements made in this press release that relate to our future contract revenues among other things involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. We undertake no obligation to update "forward-looking" statements.For Media Enquiries and Investor Relations, please contact:jcse@preciouscomms.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Huisen Household Announces 2022 Interim Results

HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - China's major furniture product manufacturer Huisen Household International Group Ltd. ("Huisen Household" or "the Group"; stock code: 2127.HK) announced unaudited interim results for the period ended 30 June 2022 ("the Reporting Period") yesterday. During the reporting period, the weak real estate market and the interest rate hike caused a contraction in the number of deals made. Inflation caused by the quantitative easing policy started to emerge during 2022, fuelling the uncertainties of economy. Reduction in subsidy, the U.S. housing price remained at a high level, and the rise in interest rate have all contributed to the plunge in the number of property transaction, leading to a relatively weak demand for furniture in the first half of 2022.In the first half of 2022, The Group's revenue was approximately RMB1.96 billion, representing a decrease of approximately 18.3% from approximately RMB2.40 billion compare to the same period of 2021. Profit was approximately RMB298.0 million, representing a decrease of approximately 29.2% from approximately RMB420.8 million compare to the same period of 2021.Mr. Zengming, chairman and executive director, said: "The weakened real estate markets in Europe and U.S. and a relatively faint furniture market have led to the decrease in the number of orders from the major customers of the Group. Notwithstanding the drop in revenue during the reporting period, the Group has successfully expanded its business to certain small and medium size enterprises customers and products were sold to more different countries or regions gradually. During the reporting period, we have reached an agreement of cooperation with Home-depot, a well-known chain store of furniture in U.S., orders from Home-depot have been increased progressively." Panel-type FurnitureDuring the reporting period, the decrease in demand from the overseas market such as the U.S. led to a decrease in revenue of panel-type furniture from approximately RMB2.26 billion to approximately RMB1.85 billion for the reporting Period, representing a decrease of 17.9%. The decrease in gross profit margin was mainly attributable to (i) the reduction in average selling price for some of the panel-type furniture as a result of the depreciation of RMB against U.S. dollar and (ii) the increase in the price of raw materials.Upholstered FurnitureDuring the reporting period, the revenue from upholstered furniture recorded a decrease of approximately 28.1%. The decrease in revenue was mainly due to the decrease in demand for upholstered furniture as a result of the slowdown of the the real estate market in Europe and U.S. During the Reporting Period, the average selling price for some of the upholstered furniture has been reduced as a result of the depreciation of RMB against U.S. dollar, leading to an overall decrease in the gross profit margin of the upholstered furniture.Sport-type FurnitureDuring the reporting period, the revenue from sport-type furniture amounted to RMB53.9 million, representing a decrease of 22.8% from the corresponding period of 2021, mainly due to the decrease in order during the Reporting Period. The gross profit margin of sport-type furniture decreased from 30.1% in the corresponding period of 2021 to 26.6% in the Reporting Period, mainly due to the reduction in the selling price of some of the products. Looking to the second half of 2021, During the reporting period, the Group continued to strengthen its original design capability and launch more original design manufacturing ("ODM") products. Revenue of ODM furniture accounted for more 81.1% of the Group's total sales for the Reporting Period, and the proportion maintained at above 80%. Original Equipment Manufacturing ("OEM") Furniture accounted for 18.9%.On 6 January 2022, the Group entered into an agreement with the local government authority to obtain the right to use two parcels of land with a total area of 33,539.30 sq.m. and on 24th August 2022 obtain the right to use another two parcels of land with 65,556.80 sq.m. in Nankang District, Ganzhou. Those four lands are nearby with total area 99,096.10 sq.m. are mainly for the construction of a new plant which will specialise in the manufacturing of particleboard, a major material used in the production of furniture products. The new plant is close to the factory operated by Ganzhou Aigesen Wood Panel Co., Ltd*.For improving and optimizing the marketing and advertising campaign of the Group and to better promote the smart furniture products of the Group, the Group has entered into a strategic cooperation agreement with Netjoy Holdings Limited (stock code: 2131) ("Netjoy"), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 24th January 2022. The Group and Netjoy shall jointly cooperate for the development of a cloud-based virtual reality smart home project based on Metaverse, including but not limited to developing virtual reality exhibition hall for consumers' interactive experience, live broadcast sales by artificial intelligence ("AI") sales anchor and promotion and sales of the smart home products of the Group through the application of AI technologies.Looking ahead to the second half of 2022, though various countries have already relaxed the social distancing measures and travel restriction, with the energy crisis in Europe and the pressure of high inflation in the U.S., the market sentiment in the private housing market in Europe and U.S. is difficult to rebound swiftly, it is expected that the export of furniture made in China would still experience a period of depression. The "World Furniture Outlook 2022" issued by Centre for Industrial Studies (CSIL) of Italy predicts that the growth in global furniture consumption could be around 4% in 2022, and the market performance for European and Asian countries are better than that as compared to other countries. While the growth is relatively minimal, the group will continue to uphold its business strategy to continuously explore markets outside U.S., establish strong relationship with new customers, and continually strengthens the ODM capabilities, making advancement of invested projects with the raised funds in a down-to-earth manner. We will also solidify our core competitiveness, and continuously increasing our market share, thus to keep on to be the leading force while being the leader of the panel type furniture industry.About Huisen Household International Group Limited We are a manufacturer of furniture products in the PRC with a primary focus on the manufacture and sales of panel furniture by way of ODM. Over 80 % of our revenue from our furniture products was generated from our ODM business and the remaining was generated from our OEM business. All of the products we produced for sales were not under our own brands. Our vertically integrated business model allows us to combine our in-house product design and development expertise with our integrated manufacturing platform, providing full range services covering product design and development, manufacture and sales of panel furniture, and securing stable supply of our principal production materials, i.e., particleboards and steel tubes by manufacturing them on our own. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Bank of Qingdao Announced its 2022 Interim Results ACN Newswire

Bank of Qingdao Announced its 2022 Interim Results

HONG KONG, Aug 26, 2022 - (ACN Newswire via SEAPRWire.com) - Bank of Qingdao Co., Ltd. ("Bank of Qingdao" or the "Bank"), the largest City Commercial Bank in Shandong Province, China, announced its interim results for the six months ended June 30, 2022 (the "Reporting Period").In the first half of 2022, problems such as supply chain disrupted by the epidemic and energy shortages caused by the Russia-Ukraine conflict continued to ferment and the risk of global economic "stagflation" increased. However, the Bank of Qingdao has always centering on the development vision of "Innovative Finance, Brilliant Banking", the Bank is firmly committed to the strategic goal of "being a technology-driven bank that offers new quality financial products with lean management and outstanding features", the sustainable development capacity of the Bank is constantly enhanced, and set a record against the market.The Net Profit Increased Stably Credit Assets Increased SteadilyBank of Qingdao continued optimizing the structure of asset and liability while increasing support to the real economy, and strove to expand its intermediary services. As at the end of the Reporting Period, the Company's operating income amounted to RMB6.211 billion, representing an increase of RMB884 million or 16.60% YoY. In addition, during the reporting period, total customer deposits reached about RMB 330.030 billion, an increase of 5.26%. Among them, personal deposits broke through the 120 billion mark, an increase of 3.77%.In terms of performance indicators, the company's net profit increased rapidly. During the Reporting Period, the accumulated net profit was RMB2.060 billion, representing an increase of 12.40% over the same period of last year. Net profit attributable to shareholders of the parent company amounted to RMB2.018 billion, representing a year-on-year increase of 12.28%.In terms of asset quality, Bank of Qingdao continuously strengthened the quality control of credit assets. While the credit assets grew steadily, the bank strengthening the comprehensive remediation of overdue loans, non-performing loans and other risky loans and strived to minimize the cost of each risk. The credit quality maintaining steady and promising. As at the end of the Reporting Period, the non-performing loans ratio of bank continuously stable and declining, the non-performing loans ratio decreased by 0.01 percentage point as compared with that at the end of last year to 1.33%. Provision coverage ratio was 209.07%, representing an increase of 11.65 percentage points as compared with that at the end of the previous year, further improve the ability of risk resistance.Meanwhile, Bank of Qingdao expanded its credit support for the real economy and increased its risk-weighted assets. In terms of capital replenishment, the Company raised a net capital of RMB4.154 billion through A share and H share rights issue, to supplement core tier-one capital, improve the level of capital adequacy, and further improve its capacities on risk resistance and supporting the development of the real economy. Retail bankingDuring the Reporting Period, Bank of Qingdao saw record new retail customers in a continuously optimized customer base structure, the bank held RMB276.398 billion assets of retail customers, representing an increase of RMB22.490 billion or 8.86% as compared with that at the end of the previous year. Besides, the retail strategy of the bank achieved remarkable results, retail deposits continued to grow while the payroll credit business was booming, the balance of the Bank's retail deposits amounted to RMB128.674 billion, representing an increase of RMB18.244 billion or 16.52% as compared with that at the end of the previous year, accounting for 38.99% of total customer deposits, representing an increase of 3.77 percentage points as compared with that at the end of the previous year.In terms of retail loans, Bank of Qingdao developed inclusive finance and provided loan services for individual industrial commercial households and small and micro enterprises. On the premise of meeting the regulatory requirements, it steadily developed personal housing loans and increased the proportion of Internet loans granted in the province to build its own Internet loan brand. During the Reporting Period, the Bank vigorously developed its self-operated Internet loan "Hairong Yidai" by launching "Hairong Yidai - Convenient Loans" for residents in the province and optimizing such products as "rural revitalization loan" and "easy loans for stores", thereby forming a complete sequence of self-operated Internet loan products. As at the end of the Reporting Period, the business balance from "Hairong Yidai" reached RMB169 million, representing an increase of 233.80% as compared with that at the end of the previous year.In terms of credit card business, Bank of Qingdao upheld the principle of prudent risk management for its credit card business by strengthening operational compliance and developing customer base. During the Reporting Period, the accumulated transaction amount was RMB36.921 billion, representing a year-on-year increase of 56.31%.In term of the wealth management and private banking business, Bank of Qingdao adhering to the "customer-centric and market-oriented" service philosophy, the Bank is committed to building a professional service team and implementing customer segmentation by leveraging on market opportunities, so as to improve its customer service capabilities and drove a steady increase in the number of customers and asset size. As at the end of the Reporting Period, the Bank had 53.6 thousand retail customers with assets under management of over RMB1 million, an increase of 4.1 thousand or 8.28% from the end of the previous year, for a total of RMB123.772 billion assets managed by the Bank, an increase of RMB9.812 billion or 8.61% from the end of the previous year.In term of the customer service management, warm service is the operating feature of Bank of Qingdao. The bank has always attached importance to the promotion of network services, creating industry benchmarking and delivering "BQD services". The bank closely aligning with the theme of retail business development in service management, with continuous efforts to promote service experience management, and further expanded the intension and extension of BQD service. From the earliest standardized service to the warm service and then to the current advocated value-based service, BQD services always focus on customer needs, continuously optimized and adjusted the way of service management, coordinated and formed a synergy to improve customer experience, builds a closed loop from service quality management to service experience management, creating a new advantage of value-based service management to establish its core competitiveness in user experience, thus break new ground for the service management value.Corporate bankingIn terms of corporate banking, Bank of Qingdao established a grid-based marketing system and a front-end marketing mechanism to strengthen the service support capability of the headquarters. In addition, the Bank made precise efforts to expand customer base, increased income from intermediary business and reduced capital expenditures, driving a steady growth in corporate business. Bank of Qingdao's corporate deposits gained momentum. The Bank achieved steady growth in corporate deposits by capturing policy opportunities through "headquarter-to-headquarter" marketing, reaching out to industrial customers and acquiring customers from the source in bulk. The balance of corporate deposits (excluding accrued interest) reached RMB201.246 billion, accounting for 60.98% of the balance of various deposits (excluding accrued interest). During the Reporting Period, the Bank's efforts in customer base construction gradually emerged as a driver for increased deposits, with the average daily deposits from new corporate customers increasing by RMB3.610 billion and the average daily deposits from strategic customers at headquarter level reaching RMB82.820 billion, representing an increase of RMB11.551 billion as compared with that at the end of the previous year.In terms of the corporate loans, Bank of Qingdao fully implemented the new development concept with focusing on green and low-carbon development to develop a distinctive blue-finance brand. During the Reporting Period, amid challenges from economic downturn and decline in effective demand, the Bank seized quality assets and increased its credit facilities, balance of corporate loans (including discounted bills and excluding accrued interest) amounted to RMB189.087 billion, representing an increase of RMB21.624 billion as compared with that at the end of the previous year, representing an increase of 12.91%.In terms of the corporate customers, Bank of Qingdao revolving around customers, focused on building the customer base by promoting "the basic management and grass-roots management strategy" to expand foundational customer base, and adhering to hierarchical management to optimize customer structure, so as to achieve increased number and improved quality of customers. During the Reporting Period, the Bank paid close attention to the reserve of high-quality projects, followed major national and regional strategic plans and provincial and municipal industrial development plans, and strengthened accurate marketing to listed or to-be-listed, specialized, fine, characteristic and innovative companies specializing in green finance, blue finance and carbon finance. As at the end of the Reporting Period, the total corporate customers who have opened accounts with the Bank amounted to 194.2 thousand, representing an increase of 14.5 thousand or 8.07% from the end of the previous year. As at the end of the Reporting Period, Bank of Qingdao continued to adhere to the inclusive business development policy of "serving small and micro enterprises (SMEs) based on the local economy", and to focus on the three business directions of "technological finance, agricultural finance and livelihood finance" for strengthening product innovation and improving service level, so as to support development of SMEs. Since the epidemic, the Bank has implemented the support policies of governments at all levels and regulatory authorities for SMEs by launching "Easy Loan", "Growing Loan", "e Tax Loan" and other characteristic businesses, to fully support SMEs to fight against the epidemic and resume production. As at the end of the Reporting Period, the balance of inclusive loans to SMEs amounted to RMB25.578 billion, up by RMB3.572 billion or 16.23% from the end of the previous year, higher than the growth of the Bank's all other loans.Financial Market BusinessIn terms of the financial market business, Bank of Qingdao optimized the asset structure, and adhered to the development principle of light capital to enrich investment varieties for multiple channels to increase income and profits. The Bank actively promoted the issuance of capital bonds with no fixed term to provide strong support for business development. While continuously strengthening the comprehensive strength of wealth management, the Bank continued to enrich the product portfolios to give play to marketing commission channels. In addition, the Bank gave full play to the advantages of corporate banking qualification to expand the coverage of issuance and underwriting business, which significantly improved the depth and breadth of investment banking business, and increased its brand influence year by year. Bank of Qingdao responded to regulatory orientation, focused on market changes, continued to optimize the investment structure, actively participated in market transactions, adhered to the principle of light-capitalization development, increased total assets while controlling the capital consumption ratio, strengthened the swing trading of standardized assets, and improved comprehensive profitability. As at the end of the Reporting Period, the Bank's proprietary amounted to RMB203.933 billion, representing an increase of RMB20.370 billion or 11.10% as compared with that at the end of last year. Among them, the scope of bond investment reached RMB129.986 billion, representing an increase of RMB18.077 billion or 16.15% as compared with that at the end of last year, mainly due to the increase in investment in non-financial corporate bonds, local government bonds and railway bonds; RMB40.776 billion investments in public fund products, representing an increase of RMB803 million or 2.01% as compared with that at the end of last year, mainly due to the increased investment in bond-type public funds. In terms of the Interbank business, Bank of Qingdao actively responded to the new market making rules, and obtained the qualifications as a spot bond market maker in the bond market, becoming the first city commercial bank spot bond market maker in Shandong Province. During the Reporting Period, the Bank continued to obtain the primary dealer qualification for open market business in 2022. Through reasonable pricing and continuous and stable financing, the Bank actively carried out various businesses, continuously improved the quality and comprehensive strength of interbank market transactions, and gave full play to the active role of primary dealers in the open market, contributing to the healthy and stable operation of the interbank market business.During the Reporting Period, the net value of the Bank of Qingdao wealth management products was stable, with obvious comparative advantages among peers. The Bank has established and issued industry-themed fixed-term products, with product series continuing to be enriched. According to the Ranking Report on Wealth Management Capability of Banks (2022 Q2)" released by PY Standard, BQD Wealth Management, Bank of Qingdao's wholly-owned subsidiary, ranked sixth in comprehensive wealth management capability among urban and commercial wealth management institutions. Moreover, BQD Wealth Management was awarded the Golden Honor Award for Outstanding ROI Wealth Management Companies and Golden Honor Award for Outstanding Innovative Wealth Management Companies by PY Standard again by virtue of its excellent comprehensive strength and good customer reputation, proved the Bank's external wealth management financing channel expansion achieved fruitful results, and the management scale and profitability achieved a steady increase.During the Reporting Period, the scope and of scale of investment banking business of Bank of Qingdao has been significantly improved, so did the Bank's brand influence. During the Reporting Period, the Bank recorded the best prices of many projects among those comparables, allowing the Bank to satisfy the low-cost financing needs of good large businesses with less capital, which thus increased the customer loyalty and enhanced customer relationship. Besides, the Bank seized the opportunity for issuance and achieved good performance, and therefore established its image in the bond market by virtue of its excellent comprehensive business capabilities. During the Reporting Period, the Bank ranked first in terms of both scale and number of underwritings among issuers with corporate credit of AA and AA+ in Shandong Province, shown a competitive edge in field of marketization of bond business.In the second half of 2022, China's economy will continuously recover, meanwhile, the "The 20th National Congress of the Chinese Communist Party" will be held in the second half of 2022. This is an important moment for comprehensively building a modern socialist country and marching on a new journey toward the second centenary goal, and the Shandong Province and Qingdao City will continue to promote the replacement of old growth drivers with new ones for optimisation and acceleration. The positive fiscal policy will enhance its effectiveness in all-around way, together with the supports of the stable monetary policy in its aggregate structure and the regulatory policy to stabilise growth and adjust structures, the pressure on the banking sector is expected to ease gradually. Bank of Qingdao will continue to adhere to the basic operation guiding ideology of "deep cultivation and fine operation, intensified promotion, optimized structure, and sustained development" by taking concerted efforts and actions at all levels of the Bank proactively and quickly, and seizing the market to continue the solid development momentum in the first half of the year, so as to ensure the full completion of the annual operating plan. About Bank of Qingdao Co., Ltd.Bank of Qingdao Co., Ltd. Is founded in Nov 1996, which is the first main board listed bank in Shandong Province and the second "A + H" share listed city commercial bank in China. It has ranked among the 500 top banks in the world for many consecutive years. In Dec 2015, the company was listed on the main board of the stock exchange of Hong Kong (03866.HK). In Jan 2019, the company was listed on Shenzhen Stock Exchange (002948.SZ). Bank of Qingdao mainly provides customers with services and products such as corporate and personal deposits, loans, payment and settlement. Driven by the development of retail banking, corporate banking and financial market, the bank initially formed a relatively solid customer base and explored a development path with distinctive characteristics and high quality. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Jacobson Pharma Announces FY2022 Annual Results ACN Newswire

Jacobson Pharma Announces FY2022 Annual Results

HONG KONG, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").KEY HIGHLIGHTS-- Year-on-year revenue up by 10.3%, amounting to HK$1,595.5 million -- Profit for the year up by 78.4%*, amounting to HK$187.7 million-- Strong growth witnessed on key therapeutic classes for chronic diseases such as lipid lowering agents and angiotensin II inhibitors -- Progress with expansion plan in Greater China as facilitated by Greater Bay Area ("GBA") healthcare policy and formation of joint venture with an established partner-- Delivery of approximately 9 million doses of Fosun BioNTech Comirnaty Vaccine in Hong Kong and Macau for the collaborative fight against COVID-19 During the Reporting Period, the Group delivered total revenue of HK$1,595.5 million with a year-on-year growth of 10.3%, primarily driven by the solid growth momentum of business in the public sector. The profit from operations and profit for the year was registered at HK$260.9 million and HK$187.7 million, representing a promising growth of about 48.9%* and 78.4%* respectively, as compared to the adjusted profit from operations* and adjusted profit* for the corresponding year of 2021. The Group's financial position remains stable as supported by a healthy cash flow, with adjusted earnings before interest, taxes, depreciation and amortisation (adjusted EBITDA) posted at HK$441.6 million for the Reporting Period and a net gearing ratio at 29.2% as of 31 March 2022. With a cash balance of HK$478.7 million as of the end of the Reporting Period, the Group also recently secured a syndicated loan of HK$1.4 billion to enhance its capital capability. The Board has recommended the payment of a final dividend of HK2.68 cents per share (FY2021: HK1.50 cents per share). Excluding the FY2021 special interim dividend in the form of distribution in specie of shares of JBM (Healthcare) Limited (Stock code: 2161.HK), an indirectly non-wholly owned subsidiary of the Company, total dividend for the Reporting Period amounts to HK3.88 cents per share (FY2021: HK2.30 cents per share), an increase of 68.7%.Solid Performance of Generics BusinessThe Group's generic drugs business demonstrated a resilient performance amidst the COVID-19 pandemic, presenting a solid growth of 13.6%, with revenue posted at HK$1,191.3 million for the Reporting Period. The Group's product offerings in the key therapeutic classes for chronic diseases such as diabetes and cardiovascular disease achieved high double-digit growth. For instance, the lipid-lowering product class recorded a strong growth of 37.2% in sales during the Reporting Period. In addition, the oncology drug class has also shown a significant growth of 572.6%, owing to the increased acceptance of the new Arsenic Trioxide Oral Solution.As a major supplier of essential medicines in Hong Kong, the Group responded swiftly to cater to the surged demand for medications during the fifth wave of the epidemic. This was reflected by the strong growth in the Group's analgesics (+18.6%), cough & cold preparations (+45.8%) and anti-inflammatory products (+77.5%). Steady Pipeline and Portfolio EnhancementThe Group continued to make steady progress with its research and development ("R&D") pipeline. As of 31 March 2022, the Group has a total of 172 products in the pipeline, among which 54 items have been approved for registration, 15 of them have been submitted for registration, 52 items have finished the development stage and are under stability preparation or stability study, plus 25 items are currently under formulation or pre-formulation research development stage.As a continuous drive for portfolio enhancement, the Group launched a number of new products during the Reporting Period, including Rabeprazole Tablets, Valsartan and Amlodipine Tablets, Telmisartan and Hydrochlorothiazide Tablets, Pregabalin Capsules, Atosiban Injection, and Idarubicin Injection. Additionally, the Group has secured the registration approvals for a group of new products such as Levetiracetam Tablets, Febuxostat Tablet, Dexmedetomidine Infusion, Pramipexole Extended Released Tablets, Brimonidine and Timolol Eye Drops, Telmisartan and Amlodipine Tablets for upcoming market launches. Tapping Specialty Drugs Market in China and AsiaFacilitated by new measures under the "Work Plan for Regulatory Innovation and Development of Pharmaceutical and Medical Devices in the Guangdong-Hong Kong-Macau Greater Bay Area", the Group has established collaboration with the University of Hong Kong-Shenzhen Hospital for the introduction of its Arsenic Trioxide Oral Solution (indicated for the treatment of acute promyelocytic leukaemia) into designated hospitals in the Greater Bay Area. The collaboration will also be part of a multi-centre clinical trial covering Guangdong, Singapore and Hong Kong. More recently, the Group, together with its non-wholly owned subsidiary, JBM (Healthcare) Limited (Stock code: 2161.HK), formed a joint venture with Ban Loong Holdings Limited (Stock code: 0030.HK), a company of which Yunnan Baiyao Group Co., Ltd (Stock code: 0538.SZ) is the controlling shareholder, to capture the growth opportunities of the specialty medicines in Greater China and the Asia-Pacific region. The joint venture will be primarily engaged in exploring business opportunities in various growth streams including specialty medicines (including orphan drugs), over-the-counter drugs, and branded healthcare products as well as medical devices in the Greater China region.Distribution of Fosun BioNTech Comirnaty Vaccine in Hong Kong and MacauThe Group is the exclusive distributor of Fosun BioNTech Comirnaty Vaccine (the "Vaccine") in Hong Kong and Macau. Up to the end of the Reporting Period, the Group delivered approximately 9 million doses of the Vaccine to the Department of Health and community vaccination centres in Hong Kong and the Macau governments. To protect the public against COVID-19 and help ensure herd immunity through vaccination, the Group is committed to supporting the governments and professional partners in the acceleration of vaccination in Hong Kong and Macau, especially among the elderly, and will continue to collaborate with the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and its subsidiaries to supply booster vaccination doses for the public, as encouraged by the health authorities.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, concluded, "While the pandemic continues to impact the market environment, the Group delivered a solid performance in FY2022 by focusing on strong execution, bolstered by our core capabilities and enhanced product pipeline and portfolio. We also take pride in playing a collaborative role in the distribution of the Fosun BioNTech Comirnaty Vaccine in Hong Kong and Macau and have demonstrated our commitment to robust manufacturing and logistics operations by ensuring a continuous supply of our essential medicines were delivered to hospitals and patients during Hong Kong's fifth wave of the epidemic."Looking ahead, we are entering 2022 with positive momentum as we aim to build a differentiated portfolio that anticipates future healthcare needs. By executing our R&D and in-licensing strategies, fostering strong partnerships, and cementing our foothold in key strategic markets, we will further diversify and transform our business, bringing sustainable growth and value to shareholders."About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high-value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com * Excluding the one-off Employment Support Scheme subsidy from the Hong Kong Government of about HK$81.1 million in FY2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More